Ricard Masia
Senior Director, Translational Medicine Crossbow Therapeutics
Seminars
Wednesday 20th May 2026
Preclinical Characterization of CBX‑663, a First‑in‑Class TCR Mimetic T‑Cell Engager Targeting TERT for Solid & Hematologic Malignancies
9:00 am
- Rationale for Crossbow Therapeutics’ approach to TERT targeting and for CBX-663 design
- In vitro binding and in vitro potency against cancer cell lines, demonstrating superior potency of bivalent vs. monovalent format (2+1 vs 1+1)
- In vivo efficacy in mouse CDX models of AML and NSCLC, and in vitro and in vivo safety with focus on bone marrow progenitor cells
